RD13-02 CAR-T Cell Therapy in Type 1 Diabetes Mellitus

Phase 1, open-label, single-arm trial of RD13-02 in type 1 diabetes mellitus (T1D), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Incidence of dose-limiting toxicities (DLTs), adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs) at 3 months and Change from baseline in 4-hour MMTT C-peptide AUC at 12 months. Started Apr 2026; status: recruiting.